Clinical, cellular, and molecular factors that contribute to antifungal drug resistance

Clinical Microbiology Reviews

Volumn 11, Issue 2, 1998, Pages 382-402

  White, Theodore C ^a,d   Marr, Kieren A ^b,e   Bowden, Raleigh A ^c,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ENZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW TRANSPLANTATION; CANDIDA ALBICANS; CLINICAL FEATURE; CYTOLOGY; DISEASE SEVERITY; GENE EXPRESSION; GENE MUTATION; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR BIOLOGY; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PHENOTYPE; REVIEW; STRAIN DIFFERENCE;

CANDIDA ALBICANS;

EID: 0031969879     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.11.2.382     Document Type: Review

References (229)

1. Alarco, A. M., I. Balan, D. Talibi, N. Mainville, and M. Raymond. 1997. AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily. J. Biol. Chem. 272:19304-19313.
2. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
3. Alexander, B. D., and J. R. Perfect. 1997. Antifungal resistance trends towards the year 2000: Implications for therapy and new approaches. Drugs 54:657-678.
4. Arthington, B. A., L. G. Bennett, P. L. Skatrud, C. J. Guynn, R. J. Barbuch, C. E. Ulbright, and M. Bard. 1991. Cloning, disruption and sequence of the gene encoding yeast C-5 sterol desaturase. Gene 102:39-44.
5. Baily, G. G., C. B. Moore, S. M. Essayag, S. deWit, J. P. Burnie, and D. W. Denning. 1997. Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 25:161-163.
6. Baily, G. G., F. M. Perry, D. W. Denning, and B. K. Mandai. 1994. Fluconazole-resistant candidosis in an HIV cohort. AIDS 8:787-792.
7. Barchiesi, F., L. F. DiFrancesco, and G. Scalise. 1997. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41:1812-1814.
8. Barchiesi, F., R. J. Hollis, M. Del Poeta, D. A. McGough, G. Scalise, M. G. Rinaldi, and M. A. Pfaller. 1995. Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed-field gel electrophoresis. Clin. Infect. Dis. 21: 561-564.
9. Barchiesi, F., R. J. Hollis, D. A. McGough, G. Scalise, M. G. Rinaldi, and M. A. Pfaller. 1995. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin. Infect. Dis. 20:634-640.
10. Bard, M., D. A. Bruner, C. A. Pierson, N. D. Lees, B. Biermann, L. Frye, C. Koegel, and R. Barbuch. 1996. Cloning and characterization of ERG25, the Saccharomyces cerevisiae gene encoding C-4 sterol methyl oxidase. Proc. Natl. Acad. Sci. USA 93:186-190.
11. Bard, M., N. D. Lees, T. Tun, D. Craft, L. Cofrin, R. Barbuch, C. Koegel, and J. C. Loper. 1993. Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 28:963-967.
12. Barrett-Bee, K. J., A. C. Lane, and R. W. Turner. 1986. The mode of antifungal action of tolnaftate. J. Med. Vet. Mycol. 24:155-160.
13. Bart-Delabesse, E., P. Boiron, A. Carlotti, and B. Dupont. 1993. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J. Clin. Microbiol. 31:2933-2937.
14. Bart-Delabesse, E., H. van Deventer, W. Goessens, J. L. Poirot, N. Lioret, A. van Belkum, and F. Dromer. 1995. Contribution of molecular typing methods and antifungal susceptibility testing to the study of a candidemia cluster in a burn care unit. J. Clin. Microbiol. 33:3278-3283.
15. Becker, J. M., L. K. Henry, W. Jiang, and Y. Koltin. 1995. Reduced virulence of Candida albicans mutants affected in multidrug resistance. Infect. Immun. 63:4515-518.
16. Ben-Yaacov, R., S. Knoller, G. A. Caldwell, J. M. Becker, and Y. Koltin. 1994. Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrob. Agents Chemother. 38:648-652.
17. Bennett, J. E. 1996. Antimicrobial agents: antifungal agents, p. 1175-1190. In A. G. Gilman, T. W. Rail, A. S. Nies, and P. Taylor (ed.), Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. Perganon Press, Inc., Elmsford, N.Y.
18. Boerlin, P., M. Addo, P. F. Boerlin, C. Durussel, J. L. Pagani, J. P. Chave, and J. Bille. 1995. Transmission of oral Candida albicans strains between HIV-positive patients. Lancet 345:1052-1053.
19. Boiron, P., E. Drouhet, B. Dupont, and L. Improvisi. 1987. Entry of ketoconazole into Candida albicans. Antimicrob. Agents Chemother. 31:244-248.
20. Borst, P. 1991. Genetic mechanisms of drug resistance. A review. Acta Oncologica 30:87-105.
21. Broughton, M. C., M. Bard, and N. D. Lees. 1991. Polyene resistance in ergosterol producing strains of Candida albicans. Mycoses 34:75-83.
22. Burgener-Kairuz, P., J. P. Zuber, P. Jaunin, T. G. Buchman, J. Bille, and M. Rossier. 1994. Rapid detection and identification of Candida albicans and Torulopsis (Candida) glabrata in clinical specimens by species-specific nested PCR amplification of a cytochrome P-450 lanosterol-alpha-demethylase (L1A1) gene fragment. J. Clin. Microbiol. 32:1902-1907.
23. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
24. Cameron, M. L., W. A. Schell, S. Bruch, J. A. Bartlett, H. A. Waskin, and J. R. Perfect. 1993. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 37:2449-2453.
25. Casadevall, A., E. D, Spitzer, D. Webb, and M. G. Rinaldi. 1993. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob. Agents Chemother. 37:1383-1386.
26. Chen, C., T. G. Turi, D. Sanglard, and J. C. Loper. 1987. Isolation of the Candida tropicalis gene for P450 lanosterol demethylase and its expression in Saccharomyces cerevisiae. Biochem. Biophys. Res. Commun. 146:1311-1317.
27. Cherry, J. M., C. Adler, C. Ball, S. Dwight, S. Chervitz, Y. Jia, G. Juvik, S. Weng, and D. Botstein. 1997. Saccharomyces Genome Database. http:// genome-www.stanford.edu/Saccharomyces/.
28. Clark, F. S., T. Parkinson, C. A. Hitchcock, and N. A. R. Gow. 1996. Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species-possible role for drug efflux in drug resistance. Antimicrob. Agents Chemother. 40:419-425.
29. Cumo, J. A., and W. E. Dismukes. 1994. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330:263-272.
30. Conly, J., R. Rennie, J. Johnson, S. Farah, and L. Hellman. 1992. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J. Infect. Dis. 165:761-764.
31. Currie, B., H. Sanati, A. S. Ibrahim, J. E. Edwards, Jr., A. Casadevall, and M. A. Ghannoum. 1995. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob. Agents Chemother. 39:1934-1937.
32. Cutler, J. E. 1991. Putative virulence factors of Candida albicans. Annu. Rev. Microbcol. 45:187-218.
33. DelSorbo, G., A. C. Andrade, J. G. M. VanNistelrooy, J. A. L. VanKan, E. Balzi, and M. A. DeWaard. 1997. Multidrug resistance in Aspergillus nidulans involves novel ATP-binding cassette transporters. Mol. Gen. Genet. 254:417-426.
34. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414.
35. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41: 1364-1368.
36. De Waard, M. A., and J. G. Van Nistelrooy. 1981. Induction of fenarimol-efflux activity in Aspergillus nidulans by fungicides inhibiting sterol biosynthesis. J. Gen. Microbiol. 126:483-489.
37. De Waard, M. A., and J. G. M. Van Nistelrooy. 1980. An energy-dependent efflux mechanism for fenarimol in a wild-type strain and fenarimol-resistant mutants of Aspergillus nidulans. Pestic. Biochem. Physiol. 13:255-266.
38. DeWit, S., D. Weerts, H. Goossens, and N. Clumeck. 1989. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet i:746-748.
39. Dick, J. D., B. R. Rosengard, W. G. Merz, R. K. Stuart, G. M. Hutchins, and R. Saral. 1985. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann. Intern. Med. 102:67-68.
40. Ding, J. C., M. Bauer, D. M. Diamond, M. A. Leal, D. Johnson, B. K. Williams, A. M. Thomas, L. Najvar, J. R. Graybill, and R. A. Larsen. 1997. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41:1589-1593.
41. Doignon, F., M. Aigle, and G. P. Ribereau. 1993. Resistance to imidazoles and triazoles in Saccharomyces cerevisiae as a new dominant marker. Plasmid 30:224-233.
42. Dromer, F., L. Improvisi, B. Dupont, M. Eliaszewicz, G. Pialoux, S. Fournier, and V. Feuillie. 1997. Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS 11:1095-1101.
43. Eng, R. H., E. Bishburg, S. M. Smith, and R. Kapila. 1986. Cryptococcal infections in patients with acquired immune deficiency syndrome. Am. J. Med. 81:19-23.
44. Favre, B., and N. S. Ryder. 1996. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob. Agents Chemother. 40:443-447.
45. Fling, M. E., J. Kopf, A. Tamarkin, J. A. Gorman, H. A. Smith, and Y. Koltin. 1991. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol. Gen. Genet. 227:318-329.
46. Fong, I. W., R. M. Bannatyne, and P. Wong. 1993. Lack of in vitro resistance of Candida albicans to ketoconazole, itraconazole and clotrimazole in women treated for recurrent vaginal candidiasis. Genitourin. Med. 69:44-46.
47. Francis, P., and T. J. Walsh. 1992. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. 15:1003-1018.
48. Fung-Tomc, J., T. White, B. Minassian, E. Huczko, and D. Bonner. 1997. In vitro activity of BMS-207147 (ER-30346) and itraconazole against yeast strains that are resistant or dole-dependent susceptible to fluconazole, abstr. E-69, p. 126. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
49. Galgiani, J. N., J. Reiser, C. Brass, A. Espinel-Ingroff, M. A. Gordon, and T. M. Kerkering. 1987. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob. Agents Chemother. 31:1343-1347.
50. Gallagher, P. J., D. E. Bennett, M. C. Henman, R. J. Russell, S. R. Flint, D. B. Shanley, and D. C. Coleman. 1992. Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. J. Gen. Microbiol. 138:1901-1911.
51. Gallant, J. E., R. D. Moore, and R. E. Chaisson. 1994. Prophylaxis for opportunistic infections in patients with HIV infection. Ann. Intern. Med. 120:932-944.
52. Geber, A., C. A. Hitchcock, J. E. Swartz, F. S. Pullen, K. E. Marsden, K. J. Kwon-Chung, and J. E. Bennett. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes - effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39: 2708-2717.
53. Ghannoum, M. A., J. H. Rex, and J. N. Galgiani. 1996. Susceptibility testing of fungi - current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. 34:489-495.
54. Ghannoum, M. A., I. Swairjo, and D. R. Soll. 1990. Variation in lipid and sterol contents in Candida albicans white and opaque phenotypes. J. Med. Vet. Mycol. 28:103-115.
55. Gleason, T. G., A. K. May, D. Caparelli, B. M. Farr, and R. G. Sawyer. 1997. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch. Surg. 132:1197-1201.
56. Goff, D. A., S. L. Koletar, W. J. Buesching, J. Barnishan, and R. J. Fass. 1995. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin. Infect. Dis. 20:77-83.
57. Goffeau, A., J. Park, I. T. Paulsen, J. L. Jonniaux, T. Dinh, P. Mordant, and M. H. Saier. 1997. Multidrug-resistant transport proteins in yeast: complete inventory and phylogenetic characterization of yeast open reading frames within the major facilitator superfamily. Yeast 13:43-54.
58. Goldway, M., D. Teff, R. Schmidt, A. B. Oppenheim, and Y. Koltin. 1995. Multidrug resistance in Candida albicans: disruption of the BENr gene. Antimicrob. Agents Chemother. 39:422-426.
59. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, D. J. Friedman, W. G. Powderly, J. L. Silber, H. Horowitz, A. Lichtin, S. N. Wolff, S. F. Mangan, S. M. Silver, D. Weisdorf, W. G. Ho, G. Gilbert, and D. Buell. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
60. Graybill, J. R. 1988. The long and the short of antifungal therapy. Infect. Dis. Clin. North Am. 2:805-825.
61. Guinet, R., J. Chanas, A. Goullier, G. Bonnefoy, and T. P. Ambroise. 1983. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J. Clin. Microbiol. 18:443-444.
62. Hawser, S. P., and L. J. Douglas. 1995. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39: 2128-2131.
63. Haynes, M. P., P. L. Chong, H. R. Buckley, and R. A. Pieringer. 1996. Fluorescence studies on the molecular action of amphotericin B on susceptible and resistant fungal cells. Biochemistry 35:7983-7992.
64. Heald, A. E., G. M. Cox, W. A, Schell, J. A. Bartlett, and J. R. Perfect. 1996. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 10:263-268.
65. Hedstrom, L., and C. C. Wang. 1989. Purine base transport in wild-type and mycophenolic acid-resistant Tritrichomonas foetus. Mol. Biochem. Parasitol. 35:219-227.
66. Hitchcock, C. A. 1991. Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals. Biochem. Soc. Trans. 19:782-787.
67. Hitchcock, C. A. 1993. Resistance of Candida albicans to azole antifungal agents. Biochem. Soc. Trans. 21:1039-1047.
68. Hitchcock, C. A., K. J. Barrett-Bee, and N. J. Russell. 1987. Inhibition of 14 alpha-sterol demethylase activity in Candida albicans Darlington does not correlate with resistance to azole. J. Med. Vet. Mycol. 25:329-333.
69. Hitchcock, C. A., K. J. Barrett-Bee, and N. J. Russell. 1986. The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. J. Gen. Microbiol. 132:2421-2431.
70. Hitchcock, C. A., G. W. Pye, P. F. Troke, E. M. Johnson, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37:1962-1965.
71. Hitchcock, C. A., N. J. Russell, and B. K. Barrett. 1987. Sterols in Candida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4. Crit. Rev. Microbiol. 15:111-115.
72. Horsburgh, C. R., Jr., and C. H. Kirkpatrick. 1983. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am. J. Med. 74:23-29.
73. Ishida, N., Y. Aoyama, R. Hatanaka, Y. Oyama, S. Imajo, M. Ishiguro, T. Oshima, H. Nakazato, T. Noguchi, U. S. Maitra, V. P. Mohan, D. B. Sprinson, and Y. Yoshida. 1988. A single amino acid substitution converts cytochrome P450(14DM) to an inactive form, cytochrome P450SG1: complete primary structures deduced from cloned DNAS. Biochem. Biophys. Res. Commun. 155:317-323.
74. Iwen, P. C., D. M. Kelly, E. C. Reed, and S. H. Hinrichs. 1995. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin. Infect. Dis. 20:342-347.
75. Johnson, E. M., D. W. Warnock, J. Luker, S. R. Porter, and C. Scully. 1995. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J. Antimicrob. Chemother. 35:103-114.
76. Joseph-Home, T., D. Hollomon, R. S. Loeffler, and S. L. Kelly. 1995. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob. Agents Chemother. 39:1526-1529.
77. Joseph-Home, T., and D. W. Hollomon. 1997. Molecular mechanisms of azole resistance in fungi. FEMS Microbiol. Lett. 149:141-149.
78. Joseph-Horne, T., R. S. T. Loeffler, D. W. Hollomon, and S. L. Kelly. 1996. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J. Med. Vet. Mycol. 34:223-225.
79. Joseph-Horne, T., N. J. Manning, D. Hollomon, and S. L. Kelly. 1995. Defective sterol delta 5(6) desaturase as a cause of azole resistance in Ustilago maydis. FEMS Microbiol. Lett. 127:29-34.
80. Kalb, V. F., J. C. Loper, C. R. Dey, C. W. Woods, and T. R. Sutter. 1986. Isolation of a cytochrome P-450 structural gene from Saccharomyces cerevisiae. Gene 45:237-245.
81. Kan, V. L., A. Geber, and J. E. Bennett. 1996. Enhanced oxidative killing of azole-resistant Candida glabrata strains with ERG11 deletion. Antimicrob. Agents Chemother. 40:1717-1719.
82. Kelly, R., S. M. Miller, M. H. Lai, and D. R. Kirsch. 1990. Cloning and characterization of the 2,3-oxidosqualene cyclase-coding gene of Candida albicans. Gene 87:177-183.
83. Kelly, S. L., D. C. Lamb, B. C. Baldwin, A. J. Corran, and D. E. Kelly. 1997. Characterization of Saccharomyces cerevisiae CYP61, sterol delta(22)-desaturase, and inhibition by azole antifungal agents. J. Biol. Chem. 272:9986-9988.
84. Kelly, S. L., D. C. Lamb, A. J. Corran, B. C. Baldwin, and D. E. Kelly. 1995. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3-beta,6-alpha-diol. Biochem. Biophys. Res. Commun. 207:910-915.
85. Kelly, S. L., D. C. Lamb, D. E. Kelly, J. Loeffler, and H. Einsele. 1996. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348:1523-1524.
86. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, H. Hebart, U. Schumacher, and H. Einsele. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Delta(5,6) desaturation. FEES Lett. 400:80-82.
87. Kelly, S. L., D. C. Lamb, M. Taylor, A. J. Corran, B. C. Baldwin, and W. G. Powderly. 1994. Resistance to amphotericin B associated with defective sterol delta 8→7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122:39-42.
88. Kenna, S., H. F. Bligh, P. F. Watson, and S. L. Kelly. 1989. Genetic and physiological analysis of azole sensitivity in Saccharomyces cerevisiae. J. Med. Vet. Mycol. 27:397-406.
89. Kirsch, D. R., M. H. Lai, and J. O'Sullivan. 1988. Isolation of the gene for cytochrome P450L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Gene 68:229-237.
90. Kohler, G., and N. Agabian. Personal communication.
91. Kovacs, J. A., A. A. Kovacs, M. Polis, W. C. Wright, V. J. Gill, C. U. Tuazon, E. P. Gelmann, H. C. Lane, R. Longfield, G. Overturf, A. M. Macher, A. S. Fauci, J. E. Parillo, J. E. Bennett, and H. Masur. 1985. Cryptococcosis in the acquired immunodeficiency syndrome. Ann. Intern. Med. 103:533-538.
92. Kurtz, M. Personal communication.
93. Kwon-Chung, K. J., and J. E. Bennett. 1992. Medical mycology, p. 81-104. Lea & Febiger, Philadelphia, Pa.
94. Lacassin, F., F. Damond, C. Chochillon, P. Longuet, J. Lebras, J. L. Vilde, and C. Leport. 1996. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis - pharmacological and mycological factors. Antimicrob. Agents Chemother. 40:1961-1963.
95. Laguna, F., J. L. Rodriguez-Tudela, J. V. Martinez-Suarez, R. Polo, E. Valencia, T. M. Diaz-Guerra, F. Dronda, and F. Pulido. 1997. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin. Infect. Dis. 24:124-130.
96. Lai, M. H., and D. R. Kirsch. 1989. Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res. 17:804.
97. Lamb, D. C., A. Corran, B. C. Baldwin, J. Kwon-Chung, and S. L. Kelly. 1995. Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients. FEBS Lett. 368:326-330.
98. Lamb, D. C., D. E. Kelly, B. C. Baldwin, F. Gozzo, P. Boscott, W. G. Richards, and S. L. Kelly. 1997. Differential inhibition of Candida albicans CYP51 with azole antifungal stereoisomers. FEMS Microbiol. Lett. 149: 25-30.
99. Lamb, D. C., D. E. Kelly, N. J. Manning, and S. L. Kelly. 1997. Reduced intracellular accumulation of azole antifungal results in resistance in Candida albicans isolate NCPF 3363. FEMS Microbiol. Lett. 147:189-193.
100. Lamb, D. C., D. E. Kelly, W. H. Schunck, A. Z. Shyadehi, M. Akhtar, D. J. Lowe, B. C. Baldwin, and S. L. Kelly. 1997. The mutation T315A in Candida albicans sterol 14 alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J. Biol. Chem. 272:5682-5688.
101. Law, D., C. B. Moore, H. M. Wardle, L. A. Ganguli, M. G. Keaney, and D. W. Denning. 1994. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemother. 34:659-668.
102. Lees, N. D., M. C. Broughton, D. Sanglard, and M. Bard. 1990. Azole susceptibility and hyphal formation in a cytochrome P-450-deficient mutant of Candida albicans. Antimicrob. Agents Chemother. 34:831-836.
103. Lees, N. D., B. Skaggs, D. R. Kirsch, and M. Bard. 1995. Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae - a review. Lipids 30:221-226.
104. Lischewski, A., M. Ruhnke, I. Tennagen, G. Schonian, J. Morschhauser, and J. Hacker. 1995. Molecular epidemiology of Candida isolates from AIDS patients showing different fluconazole resistance profiles. J. Clin. Microbiol. 33:769-771.
105. Lockhart, S. R., J. J. Fritch, A. S. Meier, K. Schroppel, T. Srikantha, R. Galask, and D. R. Soil. 1995. Colonizing populations of Candida albicans are clonal in origin but undergo microevolution through C-1 fragment reorganization as demonstrated by DNA fingerprinting and C-1 sequencing. J. Clin. Microbiol. 33:1501-1509.
106. Loffler, J., S. L. Kelly, H. Hebart, U. Schumacher, C. LassFlorl, and H. Einsele. 1997. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151:263-268.
107. Lynch, M. E., J. D. Sobel, and P. L. Fidel, Jr. 1996. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J. Med. Vet. Mycol. 34:337-339.
108. Maenza, J. R., J. C. Keruly, R. D. Moore, R. E. Chaisson, W. G. Merz, and J. E. Gallant 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 173:219-225.
109. Maenza, J. R., W. G. Merz, M. J. Romagnoli, J. C. Keruly, R. D. Moore, and J. E. Gallant. 1997. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin. Infect. Dis. 24:28-34.
110. Marger, M. D., and M. H. Saier, Jr. 1993. A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport. Trends Biochem. Sci. 18:13-20.
111. Marichal, P., J. Gorrens, M. C. Coene, L. Le Jeune, and H. Vanden Bossche. 1995. Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 38:111-117.
112. Marichal, P., and H. vanden Bossche. 1995. Mechanisms of resistance to azole antifungals. Acta Biochim. Pol. 42:509-516.
113. Marichal, P., H. Vanden Bossche, F. C. Odds, G. Nobels, D. W. Warnock, V. Timmerman, C. Van Broeckhoven, S. Fay, and P. Mose Larsen. 1997. Molecular-biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 41:2229-2237.
114. Marr, K. A., T. C. White, J. H. van Bunk, and R. A. Bowden. 1997. Development of a fluconazole-resistant Candida albicans in a patient undergoing bone marrow transplantation. Clin. Infect. Dis. 25:908-910.
115. Marriott, M. S. 1980. Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. J. Gen. Microbiol. 117:253-255.
116. Martins, M. D., M. LozanoChiu, and J. H. Rex. 1997. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 25:843-846.
117. McCullough, M., and S. Hume. 1995. A longitudinal study of the change in resistance patterns and genetic relationship of oral Candida albicans from HIV-infected patients. J. Med. Vet. Mycol. 33:33-37.
118. McGinnis, M. R., L. Pasarell, D. A. Sutton, A. W. Fothergill, C. R. Cooper, Jr., and M. G. Rinaldi. 1997. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob. Agents Chemother. 41:1832-1834.
119. Michaelis, S., and C, Berkower. 1995. Sequence comparison of yeast ATP binding cassette (ABC) proteins. Cold Spring Harbor Symp. Quant. Biol. 60:291-309.
120. Millon, L., A. Manteaux, G. Reboux, C. Drobacheff, M. Monod, T. Barale, and Y. Michel-Briand. 1994. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J. Clin. Microbiol. 32:1115-1118.
121. Miyasaki, S. H., J. B. Hicks, D. Greenspan, I. Polacheck, L. A. MacPhail, T. C. White, N. Agabian, and J. S. Greenspan. 1992. The identification and tracking of Candida albicans isolates from oral lesions in HIV-seropositive individuals. J. Acquired Immune Defic. Syndr. 5:1039-1046.
122. Miyazaki, Y., A. Geber, T. Parkinson, C. Hitchcock, and J. E. Bennett. 1997. Complementation of delta 5,6-desaturase did not restore fluconazole susceptibility in Candida albicans Darlington strain, abstr. F-81. In Abstracts of the 97th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
123. Monk, J. P., and R. N. Brogden. 1991. Naftifine. A review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs 42: 659-672.
124. Moran, G. P., D. J. Sullivan, M. C. Henman, C. E. McCreary, B. J. Harrington, D. B. Shanley, and D. C. Coleman. 1997. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41:617-623.
125. Natarajan, U., E. Brummer, and D. A. Stevens. 1997. Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole. Antimicrob. Agents Chemother. 41:1575-1578.
126. Mewman, S. L., T. P. Flanigan, A. Fisher, M. G. Rinaldi, M. Stein, and K. Vigilante. 1994. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin. Infect. Dis. 19:684-686.
127. Nguyen, M. H., L. K. Najvar, C. Y. Yu, and J. R. Graybill. 1997. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41:1120-1123.
128. Nguyen, M. H., J. E. Peacock, A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia - emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
129. Niimi, M., and R. Cannon. 1997. Multidrug resistance genes in Candida albicans. Jpn. J. Med. Mycol. 38:297-302.
130. Niimi, M., F. J. Fischer, J. Piper, H. F. Jenkinson, M. Arisawa, and R. D. Cannon. 1997. Expression of drug efflux-associated genes and multidrug resistance in Candida albicans, abstr. P456. In Abstracts of the 13th Congress of the International Society for Human and Animal Mycology.
131. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
132. Odds, F. C. 1988. Candida and candidosis: a review and bibliography. Bailliere Tindall, London, United Kingdom.
133. Odds, F. C. 1993. Resistance of yeasts to azole-derivative antifungals. J. Antimicrob. Chemother. 31:463-471.
134. Reference deleted.
135. Osaka, K., V. B. Ritov, J. F. Bernardo, R. A. Branch, and V. E. Kagan. 1997. Amphotericin B protects cis-parinaric acid against peroxyl radical-induced oxidation: amphotericin B as an antioxidant. Antimicrob. Agents Chemother. 41:743-747.
136. Pappagianis, D., M. S. Collins, R. Hector, and J. Remington. 1979. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob. Agents Chemother. 16:123-126.
137. Pappas, P. G., R. W. Bradsher, C. A. Kauffman, G. A. Cloud, C. J. Thomas, G. D. Campbell, S. W. Chapman, C. Newman, and W. E. Dismukes. 1997. Treatment of blastomycosis with higher doses of fluconazole. Clin. Infect. Dis. 25:200-205.
138. Parkinson, T., D. J. Falconer, and C. A. Hitchcock. 1995. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob. Agents Chemother. 39:1696-1699.
139. Patterson, T. F. Personal communication.
140. Paulsen, I. T., M. H. Brown, and R. A. Skurray. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60:575-608.
141. Pfaller, M. A., J. H. Rex, and M. G. Rinaldi. 1997. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin. Infect. Dis. 24:776-784.
142. Pfaller, M. A., C. J. Rhine, S. W. Redding, J. Smith, G. Farinacci, A. W. Fothergill, and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32:59-64.
143. Pittet, D., M. Monod, P. M. Suter, E. Frenk, and R. Auckenthaler. 1994. Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg. 220:751-758.
144. Powderly, W. G. 1992. Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients. AIDS 6:604-605.
145. Powderly, W. G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84:826-832.
146. Powderly, W. G., K. Robinson, and E. J. Keath. 1992. Molecular typing of Candida albicans isolated from oral lesions of HIV-infected individuals. AIDS 6:81-84.
147. Poynton, C. H. 1997. Immune modulation by cytokines in the treatment of opportunistic infections. Curr. Opin. Infect. Dis. 10:275-280.
148. Prasad, R., W. P. De, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27:320-329.
149. Price, M. F., M. T. LaRocco, and L. O. Gentry. 1994. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob. Agents Chemother. 38: 1422-1427.
150. Pujol, C., J. Reynes, F. Renaud, M. Raymond, M. Tibayrenc, F. J. Ayala, F. Janbon, M. Malli'e, and J. M. Bastide. 1993. The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients. Proc. Natl. Acad. Sci. USA 90: 9456-9459.
151. Raymond, M., D. Dignard, A.-M. Alarco, N. Mainville, B. B. Magee, and D. Y. Thomas. 1998. A Ste6/P-glycoprotein homologue from the asexual yeast, Candida albicans transports the a-factor mating phermone in Saccharomyces cerevisiae. Mol. Microbiol. 27:587-598.
152. Raymond, M., D. Dignard, N. Mainville, and D. Y. Thomas. Personal communication.
153. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, C. J. Rhine, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
154. Redondo-Lopez, V., M. Lynch, C. Schmitt, R. Cook, and J. D. Sobel. 1990. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet. Gynecol. 76:651-655.
155. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, O. P. Dib, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, and T. F. Patterson. 1996. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in Human Immunodeficiency Virus-infected patients. J. Infect. Dis. 174:821-827.
156. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, and C. D. Webb. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331:1325-1330.
157. Rex, J. H., P. W. Nelsom, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by
158. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro/in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
159. Rex, J. H., M. A. Pfaller, M. Lancaster, F. C. Odds, A. Bolmstrom, and M. G. Rinaldi. 1996. Quality control guidelines for National Committee for Clinical Laboratory Standards - recommended broth macrodilution testing of ketoconazole and itraconazole. J. Clin. Microbiol. 34:816-817.
160. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
161. Roessner, C. A., C. Min, S. H. Hardin, L. W. Harris Haller, J. C. McCollum, and A. I. Scott. 1993. Sequence of the Candida albicans erg7 gene. Gene 127:149-150.
162. Rogers, T. E., and J. N. Galgiani. 1986. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob. Agents Chemother. 30:418-422.
163. Ryder, N. S. 1992. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br. J. Dermatol. 39:2-7.
164. Safran, D. B., and E. Dawson. 1997. The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit. Arch. Surg. 132:1184-1188.
165. Sanati, H., C. F. Ramos, A. S. Bayer, and M. A. Ghannoum. 1997. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob. Agents Chemother. 41:1345-1348.
166. Sandven, P., K. Nilsen, A. Digranes, T. Tjade, and J. Lassen. 1997. Candida norvegensis: a fluconazole-resistant species. Antimicrob. Agents Chemother. 41:1375-1376.
167. Sangeorzan, J. A., S. F. Bradley, X. He, L. T. Zarins, G. L. Ridenour, R. N. Tiballi, and C. A. Kauffman. 1994. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med. 97:339-346.
168. Sanglard, D. Personal communication.
169. 168a.Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14a-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
170. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143:405-416.
171. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
172. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
173. Sanguineti, A., J. K. Carmichael, and K. Campbell. 1993. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch. Intern. Med. 153:1122-1124.
174. Sasnauskas, K., R. Jomantiene, E. Lebediene, J. Lebedys, A. Januska, and A. Janulaitis. 1992. Cloning and sequence analysis of a Candida maltosa gene which confers resistance to cycloheximide. Gene 116:105-108.
175. Scherer, S., and Y. Ran. 1996. Candida albicans information: web page. http://alces.med.umn.edu/Candida.html.
176. Schmid, J., F. C. Odds, M. J. Wiselka, K. G. Nicholson, and D. R. Soil. 1992. Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. J. Clin. Microbiol. 30:935-941.
177. Schmid, J., M. Rotman, B. Reed, C. L. Pierson, and D. R. Soil. 1993. Genetic similarity of Candida albicans strains from vaginitis patients and their partners. J. Clin. Microbiol. 31:39-46.
178. Schmid, J., E. Voss, and D. R. Soll. 1990. Computer-assisted methods for assessing strain relatedness in Candida albicans by fingerprinting with the moderately repetitive sequence Ca3. J. Clin. Microbiol. 28:1236-1243.
179. Schonebeck, J., and S. Anséhn. 1973. 5-Fluorocytosine resistance in Candida spp. and Torulopsis glabrata. Sabouraudia 11:10-20.
180. Schoofs, A., F. C. Odds, R. Colebunders, M. Ieven, L. Wouters, and H. Goossens. 1997. Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrob. Agents Chemother. 41:1625-1635.
181. Shimokawa, O., and H. Nakayama. 1992. Increased sensitivity of Candida albicans cells accumulating 14α-methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents. Antimicrob. Agents Chemother. 36:1626-1629.
182. Shyadehi, A. Z., D. C. Lamb, S. L. Kelly, D. E. Kelly, W. H. Schunck, J. N. Wright, D. Corina, and M. Akhtar. 1996. The mechanism of the acyl-carbon bond cleavage reaction catalyzed by recombinant sterol 14-alpha-demethylase of Candida albicans (other names are lanosterol 14-alpha-demethylase, P-450(14dm), and Cyp51). J. Biol. Chem. 271:12445-12450.
183. Slavin, M. A., B. Osborne, R. Adams, M. J. Levenstein, H. G. Schoch, A. R. Feldman, J. D. Meyers, and R. A. Bowden. 1995. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis. 171: 1545-1552.
184. Sobel, J. D., D. Brooker, G. E. Stein, J. L. Thomason, D. P. Wermeling, B. Bradley, and L. Weinstein. 1995. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am. J. Obstet. Gynecol. 172:1263-1268.
185. Sobel, J. D., and J. A. Vazquez. 1996. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin. Infect. Dis. 22:726-727.
186. Soll, D. R. 1992. High-frequency switching in Candida albicans. Clin. Microbiol. Rev. 5:183-203.
187. Soil, D. R., R. Galask, S. Isley, T. V. Rao, D. Stone, J. Hicks, J. Schmid, K. Mac, and C. Hanna. 1989. Switching of Candida albicans during successive episodes of recurrent vaginitis. J. Clin. Microbiol. 27:681-690.
188. Soil, D. R., B. Morrow, and T. Srikantha. 1993. High-frequency phenotypic switching in Candida albicans. Trends Genet. 9:61-65.
189. Solomkin, J. S. 1996. Timing of treatment for nonneutropenic patients colonized with Candida. Am. J. Surg. 172:44S-48S.
190. Spinillo, A., S. Nicola, L. Colonna, E. Marangoni, C. Cavanna, and G. Michelone. 1994. Frequency and significance of drug resistance in vulvovaginal candidiasis. Gynecol. Obstet. Invest. 38:130-133.
191. Stein, G. E., and N. Mummaw. 1993. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob. Agents Chemother. 37:89-92.
192. Sturtevant, J., and R. Calderone. Personal communication.
193. Sugar, A. M. 1995. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob. Agents Chemother. 39:1907-1912.
194. Swerdloff, J. N., S. G. Filler, and J. E. Edwards, Jr. 1993. Severe Candidal infections in neutropenic patients. Clin. Infect. Dis. 2:S457-S467.
195. Taglicht, D., and S. Michaelis. A complete catalogue of Saccharomyces cerevisiae ABC proteins and their relevance to human health and disease. Methods Enzymol., in press.
196. Tobin, M. B., R. B. Peery, and P. L. Skatrud. 1997. Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus. Gene 200:1-2.
197. Troillet, N., C. Durussel, J. Bille, M. P. Glauser, and J. P. Chave. 1993. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 12:911-915.
198. Tsai, H., and L. A. Bobek. 1997. Studies of the mechanism of human salivary histatin-5 candidacidal activity with histatin-5 variants and azole-sensitive and -resistant Candida species. Antimicrob. Agents Chemother. 41:2224-2228.
199. Turi, T. G., and J. C. Loper. 1992. Multiple regulatory elements control expression of the gene encoding the Saccharomyces cerevisiae cytochrome P450, lanosterol 14-alpha-demethylase (ERG11). J. Biol. Chem. 267:2046-2056.
200. Vanden Bossche, H. 1991. Ergosterol biosynthesis inhibitors, p. 239-257. In R. Prasad (ed.), Candida albicans. Springer-Verlag KG, Berlin, Germany.
201. Vanden Bossche, H., P. Marichal, L. Le Jeune, M. C. Coene, J. Gorrens, and W. Cools. 1993. Effects of itraconazole on cytochrome P-450-dependent sterol 14-alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob. Agents Chemother. 37:2101-2105.
202. Vanden Bossche, H., P. Marichal, and F. C. Odds. 1994. Molecular mechanisms of drug resistance in fungi. Trends Microbiol. 2:393-400.
203. Vanden Bossche, H., P. Marichal, F. C. Odds, L. Le Jeune, and M. C. Coene. 1992. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36:2602-2610.
204. Vanden Bossche, H., D. W. Warnock, B. Dupont, D. Kerridge, G. S. Sen, L. Improvisi, P. Marichal, F. C. Odds, F. Provost, and O. Ronin. 1994. Mechanisms and clinical impact of antifungal drug resistance. J. Med. Vet. Mycol. 32:189-202.
205. Vanden Bossche, H., G. Willemsens, and P. Marichal. 1987. Anti-Candida drugs - the biochemical basis for their activity. Crit. Rev. Microbiol. 15:57-72.
206. Vazquez, J. A., T. Lundstrom, L. Dembry, P. Chandrasekar, D. Boikov, M. B. Parri, and M. J. Zervos. 1995. Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis. Bone Marrow Transplant. 16:849-853.
207. Vazquez, J. A., and J. D. Sobel. 1997. Epidemiologie overview of resistance to oral antifungal agents in the immunocompetent host. Opportunistic infection in the immunocompromised host. Excerpta Med. Int. Congr. Ser. 1997:1-11.
208. Venkateswarlu, K., D. W. Denning, and S. L. Kelly. 1997. Inhibition and interaction of cytochrome P450 of Candida krusei with azote antifungal drugs. J. Med. Vet. Mycol. 35:19-25.
209. Venkateswarlu, K., D. W. Denning, N. J. Manning, and S. L. Kelly. 1996. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob. Agents Chemother. 40:2443-2446.
210. Venkateswarlu, K., D. W. Denning, N. J. Manning, and S. L. Kelly. 1995. Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol. Lett. 131:337-341.
211. Venkateswarlu, K., D. E. Kelly, and S. L. Kelly. 1997. Characterization of Saccharomyces cerevisiae CYP51 and a CYP51 fusion protein with NADPH cytochrome P-450 oxidoreductase expressed in Escherichia coli. Antimicrob. Agents Chemother. 41:776-780.
212. Venkateswarlu, K., M. Taylor, N. J. Manning, M. G. Rinaldi, and S. L. Kelly. 1997. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:748-751.
213. Vuffray, A., C. Durussel, P. Boerlin, P. F. Boerlin, J. Bille, M. P. Glauser, and J. P. Chave. 1994. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 8:708-709.
214. Walsh, T. J., M. Kasai, A. Francesconi, D. Landsman, and S. J. Chanock. 1997. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance. J. Med. Vet. Mycol. 35:133-139.
215. Walsh, T. J., and J. W. Lee. 1993. Prevention of invasive fungal infections in patients with neoplastic disease. Clin. Infect. Dis. 2:S468-S480.
216. Walsh, T. J., G. P. Melcher, M. G. Rinaldi, J. Lecciones, D. A. McGough, P. Kelly, J. Lee, D. Callender, M. Rubin, and P. A. Pizzo. 1990. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. 28:1616-1622.
217. Warnock, D. W. 1991. Amphotericin B: an introduction. J. Antimicrob. Chemother. 28:27-38.
218. Watson, P. F., M. E. Rose, S. W. Ellis, H. England, and S. L. Kelly. 1989. Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem. Biophys. Res. Commun. 164:1170-1175.
219. Wheat, J., P. Marichal, H. Vanden Bossche, A. LeMonte, and P. Connolly. 1997. Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum. Antimicrob. Agents Chemother. 41:410-414.
220. Whelan, W. L. 1987. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit. Rev. Microbiol. 15:45-56.
221. Whelan, W. L., and D. R. Soil. 1982. Mitotic recombination in Candida albicans: recessive lethal alleles linked to a gene required for methionine biosynthesis. Mol. Gen. Genet. 187:477-485.
222. White, T. C. 1997, Antifungal drug resistance in Candida albicans. ASM News 63:427-433.
223. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from an HIV-infected patient. Antimicrob. Agents Chemother. 41:1482-1487.
224. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14-alpha-demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
225. White, T. C. Unpublished data.
226. White, T. C., M. A. Pfaller, R. G. Rinaldi, J. Smith, and S. W. Redding. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3:S102-S109.
227. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.
228. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
229. Yoshida, Y., Y. Aoyama, T. Nishino, H. Katsuki, U. S. Maitra, V. P. Mohan, and D. B. Sprinson. 1985. Spectral properties of a novel cytochrome P-450 of a Saccharomyces cerevisiae mutant SG1. A cytochrome P-450 species having a nitrogenous ligand trans to thiolate. Biochem. Biophys. Res. Commun. 127:623-628.